We could not find any results for:
Make sure your spelling is correct or try broadening your search.
AB Science receives notice of allowance for European patent covering masitinib until 2040 in the treatment of sickle cell disease PRESS RELEASE AB SCIENCE RECEIVES NOTICE OF ALLOWANCE FOR EUROPEAN...
AB Science reçoit un avis d’acceptation pour le brevet européen couvrant jusqu’en 2040 le masitinib dans le traitement de la drépanocytose COMMUNIQUE DE PRESSE AB SCIENCE REÇOIT UN AVIS...
PRESS RELEASE AB SCIENCE RECEIVES NOTICE OF ALLOWANCE FOR EUROPEAN PATENT COVERING MASITINIB UNTIL 2040 IN THE TREATMENT OF SICKLE CELL DISEASE THIS DECISION FURTHER STRENGTHENS MASITINIB’S...
AB Science provides an update on the application for conditional marketing authorisation of masitinib in ALS PRESS RELEASE AB SCIENCE PROVIDES AN UPDATE ON THE APPLICATION FOR CONDITIONAL...
AB Science fait le point sur la demande d'autorisation de mise sur le marché conditionnelle du masitinib dans la SLA COMMUNIQUE DE PRESSE AB SCIENCE FAIT LE POINT SUR LA DEMANDE...
PRESS RELEASE AB SCIENCE PROVIDES AN UPDATE ON THE APPLICATION FOR CONDITIONAL MARKETING AUTHORISATION OF MASITINIB IN THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS Paris, 17 October, 2024...
AB Science : Résultats financiers semestriels au 30 juin 2024 et point sur les activités d’AB Science COMMUNIQUE DE PRESSE AB SCIENCE PRÉSENTE SES RÉSULTATS FINANCIERS AU PREMIER SEMESTRE...
AB Science: Revenues for the first half of 2024 and update on AB Science’s activities PRESS RELEASE AB SCIENCE PRESENTS ITS FINANCIAL RESULTS FOR THE FIRST HALF OF 2024 AND THE KEY EVENTS...
PRESS RELEASE AB SCIENCE PRESENTS ITS FINANCIAL RESULTS FOR THE FIRST HALF OF 2024 AND THE KEY EVENTS OF THE PERIOD Clinical development Masitinib platform: Ongoing re-examination by...
AB Science annonce avoir réalisé le règlement livraison de sa dernière augmentation de capital de 5,0 millions d’euros COMMUNIQUE DE PRESSE AB SCIENCE ANNONCE AVOIR REALISE LE REGLEMENT LIVRAISON...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.12 | -13.17233809 | 0.911 | 0.938 | 0.79 | 54302 | 0.86686287 | DE |
4 | -0.195 | -19.7768762677 | 0.986 | 1.05 | 0.79 | 40038 | 0.93896874 | DE |
12 | -0.287 | -26.6233766234 | 1.078 | 1.078 | 0.79 | 35025 | 0.97805967 | DE |
26 | -1.334 | -62.7764705882 | 2.125 | 2.155 | 0.79 | 70227 | 1.25149884 | DE |
52 | -2.099 | -72.6297577855 | 2.89 | 4.465 | 0.79 | 99748 | 2.23317557 | DE |
156 | -11.459 | -93.5428571429 | 12.25 | 13.34 | 0.79 | 95387 | 4.70619732 | DE |
260 | -4.239 | -84.2743538767 | 5.03 | 21.75 | 0.79 | 144936 | 8.45867132 | DE |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions